We are thrilled to announce that Queen City Angels is the lead investor in SalivIQ’s Seed round!

Over the past year, SalivIQ has made significant progress across our team, technology, and regulatory path as we move towards launching the first saliva test for strep throat. We’re deeply grateful to our Pre-Seed investors for helping us reach these milestones and to our committed Seed investors for the continued momentum we’re seeing in this round.

Having Queen City Angels as our lead investor is especially meaningful. Beyond capital, their members bring decades of experience as founders, operators, and executives, and they actively support portfolio companies through strategic guidance and mentorship, helping companies to commercialize and scale.

We’re ready for 2026! It’s time to change strep throat testing for good!